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Background: Stroke is a leading cause of mortality and morbidity. It is associated
with excessive bone loss and risk of fracture in stroke patients is high. The P2Y12R
antagonist and platelet inhibitor, clopidogrel, is widely used for secondary prevention
after a stroke. However, recent studies have shown that clopidogrel has negative
effects on bone and that long-term clopidogrel use is associated with increased fracture
risk. The purpose of the current study was therefore to investigate the association of
clopidogrel treatment with risk of fractures in stroke and TIA patients.
Methods: The study was a cohort study including all subjects who were prescribed
clopidogrel between 1996 and 2008 in Denmark (n = 77,503). Age- and gender
matched controls (n = 232,510) were randomly selected from the background
population. The study end-points were occurrence of stroke or TIA and occurrence
of fracture. Clopidogrel use was primary exposure.
Results: Ischemic stroke increased risk of fracture by 50% while haemorrhagic stroke
and TIA increased the risk by 30%. However, after adjusting for multiple confounders
only patients with ischemic stroke and haemorrhagic stroke had increased fracture
risk. Clopidogrel use was not associated with increased fracture risk in subjects with
ischaemic stroke or TIA. In contrast, after adjusting for multiple confounders clopidogrel
treatment was associated with a 10–35% reduced risk of fracture.
Conclusion: Patients with stroke have increased risk of osteoporotic fractures, but
clopidogrel treatment does not increase fracture risk. In contrast, patients less adherent
to the treatment have lower risk of fractures than non-users and patients with high
adherence. However, based on the increased risk in stroke patients, clinicians should
consider evaluation of bone status of these patients.
Keywords: stroke, antiplatelet therapy, osteoporosis, bone, fracture, P2Y12 receptor, clopidogrel
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INTRODUCTION
Stroke is one of the leading causes of mortality and morbidity
worldwide. In the surviving stroke patient the increased
functional dependence and cognitive decline often leads to
immobilization. Nearly 80–90% of all strokes occur in people
over the age of 65, adding to the risk of osteoporosis in
these patients (Truelsen et al., 2006). Balance is often impaired
after a stroke increasing the risk of falls and in combination
with immobilization and advanced age stroke patients have
multiple risk factors for fractures. After a hemiplegic stroke,
changes in bone metabolism occur already during the week
following the stroke. Serum markers of bone formation are
low and serum calcium and markers of bone resorption are
increased and negatively correlated to the level of mobilization
(Sato et al., 2000). Also, a high number of the patients
had vitamin D deficiency, as only 27% had sufficient serum
levels of vitamin D (Sato et al., 2000). Stroke patients with
hemiparesis develop a significant bone loss during the first
year after the stroke, primarily in the affected side and mainly
in the humerus (loss in bone mineral density of 17.4% after
1 year) and the proximal femur (loss of 12.2%) (Ramnemark
et al., 1999). Excessive bone loss is a clear risk factor of
osteoporosis and subsequently fractures. A recent meta-analysis
that included 13 cohorts of stroke survivors found a 50%
increased risk of hip fracture in the stroke patients compared
to healthy men and women of the same age (Yuan et al.,
2016). In a Swedish cohort of stroke patients, the risk of
fracture was 4% 1 year post-stroke, 15% after 5 years and 24%
after 10 years (Ramnemark et al., 1998). Fractures occurred
primarily after falls (84% of fractures) and mainly affected
the paretic side in patients with paresis (Ramnemark et al.,
1998). At least in younger individuals, no difference in fracture
rates was found between stroke and TIA patients (Brown
et al., 2008). Thus, post-stroke fractures may result from disuse
hemiosteoporosis, hypovitaminosis D, and an increased risk of
falls.
Treatment with platelet aggregation inhibitors has become
the gold standard for secondary prevention of recurrent non-
cardioembolic strokes after the initial episode, both in patients
with ischaemic stroke and TIA (Kernan et al., 2014). Life-
long treatment with the thienopyridine, clopidogrel, has become
one of the standard treatments in patients suffering a stroke
(Kernan et al., 2014). Clopidogrel inhibits platelet aggregation by
irreversibly binding to the P2Y12 receptor, previously called the
“platelet receptor.”
Recent studies have shown that the P2Y12 receptor is
expressed not only on platelets but also on bone cells.
Clopidogrel inhibits the function of the bone forming osteoblasts
(Syberg et al., 2012). Moreover, in a recent in vivo study
mice treated with clopidogrel had reduced bone mass and -
strength of approximately 20% (Syberg et al., 2012). Thus,
clopidogrel induced severe osteoporosis in the animals. In
addition, a large population-based register study including all
patients having prescribed clopidogrel in Denmark between
1999 and 2008 confirmed the suspected negative effects of
clopidogrel on bone, as the fracture risk was increased by
60% compared to non-clopidogrel users (Jørgensen et al.,
2012). Thus, clopidogrel treatment has clear negative effects on
bone.
As patients with ischaemic stroke and TIA are prescribed
clopidogrel for the rest of their lives and as they are already
susceptible to bone fractures, additional bone loss induced
by clopidogrel treatment may therefore increase the risk even
further. The aim of the present study was to evaluate the
association between the platelet inhibitor clopidogrel and fracture
incidence in stroke and TIA patients in a population-based
nationwide case-control study.
MATERIALS AND METHODS
Study Design
The study was designed as a cohort study. All subjects who
were prescribed clopidogrel during the years 1996 to 2008 in
Denmark were included as exposed subjects (n= 77,503), and for
each exposed subject three subjects of the same age (same birth
year) and gender were randomly selected from the background
population as controls (n = 232,510). The non-users were
selected and matched on age- and gender to the users through
an intensity sampling technique. As it is a register-based study,
no approval from the Ethics Committee is necessary and Ethics
approval was therefore not sought.
End-Points
The study end-points were occurrence of stroke or TIA
and occurrence of any fracture succeeding the stroke or
TIA (International Classification of Diseases (ICD) 10 codes:
S02.0-S02.9, S07.0-S07.9, S12.0-S12.9, S22.0-S22.9, S32.0-S32.8,
S42.0-S42.9, S52.0-S52.9, S62.0-S62.9, S72.0-S72.9, S82.0-S82.9,
S92.0-S92.9), hip fracture (S72.0 and S72.1), forearm fracture
(S52.5 and S52.6), and spine fracture (S12.0, S12.1, S12.2, S12.7,
S12.8, S12.9, S22.0, S22.1, S32.0, S32.7, S32.8) between January 1st
1996 and December 31st 2008. The vertebral fractures included
were clinical fractures collected from hospital records of patients,
who were referred to emergency rooms or other departments and
were diagnosed with a vertebral fracture.
Exposure Variables
Clopidogrel use was the primary exposure. Patterns of drug
use were analyzed for the period from January 1st, 1996 to
the date of fracture or corresponding dummy date among the
non-users. Data were collected systematically and information
on whether the drugs were used systematically or temporarily
was included in the analyses of drug use via the Defined
Daily Dose (DDD), using the dates of prescription. DDD is
used according to the WHO definition, which is defined as
the assumed average maintenance dose per day for a drug
used for its main indication in adults. The other exposure
variables were occurrence of (1) use of drugs known to
be associated with fracture risk (corticosteroids), and (2)
co-morbidities known to affect fracture risk (prior fracture
Klotzbuecher et al., 2000) and alcoholism (Kanis et al., 2005).
These factors were chosen as they were known to potentially
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affect fracture risk, and were regarded as important potential
confounders in a setting where many variables besides the
main factor may influence the risk of fractures (confounding
by indication). To analyze for confounding from use of other
cardiovascular drugs these were also included (Rejnmark et al.,
2005, 2006a,b).
Due to the imbalances in confounders typical for
observational studies, extensive confounder control was
performed including all the unevenly distributed known
confounders: Charlson index, income, living alone or not,
spironolactone use, use of bronchodilator drugs (proxy for
smoking), use of drugs for smoking cessation (proxy for
smoking), prior fracture, alcoholism, systemic corticosteroids,
statin use, ACE use, ACE+diuretics use, combined alpha plus
betablocker use, other diuretics use, betablocker use, betablocker
plus other drug combined, calcium channel blocker, thiazide
diuretics, loop diuretics, dipyridamole use, and acetylsalicylic
use. The variables were entered into the statistical analysis and
analyses for interaction were performed.
Information on bodyweight or body mass index (BMI) was not
available.
Registers Used
The information on fracture occurrence, stroke and TIA as well
as occurrence of other diseases, prior fractures, alcoholism came
from two registers: (1) The National Hospital Discharge Register
(Andersen et al., 1999), and (2) The Psychiatric Central Register
(Munk-Jørgensen and Mortensen, 1997). These have been
described in detail previously (Mosbech et al., 1995; Andersen
et al., 1999; Vestergaard and Mosekilde, 2002; Jørgensen et al.,
2012; Vestergaard et al., 2012; Grove et al., 2013).
The information on clopidogrel use came from The Danish
Medicines Agency, who keeps a nationwide register of all
drugs sold at pharmacies throughout the country from 1996
and onward (The National Pharmacological Database run
by the Danish Medicines Agency1). Any drugs bought are
registered with ATC code, dosage sold, and date of sale for
the period January 1st 1996 to December 31st, 2008. Details
about this have previously been published (Vestergaard et al.,
2012).
It is possible to link these sources of information through the
Central Person Register Number, which is a unique registration
code given to every inhabitant, enabling registration on an
individual basis.
The project was approved and controlled by the National
Board of Health, the Danish Data Protection Agency, and the
Directory board of the Psychiatric Central Register.
In Denmark almost all patients with fractures are managed
in the hospital system (also including the emergency rooms)
(Vestergaard et al., 2002), even fractures sustained abroad are
registered upon return for insurance reasons. The capture of
fractures is thus very high (Mosbech et al., 1995; Andersen
et al., 1999). The validity of a fracture diagnosis is around 93%
(Vestergaard and Mosekilde, 2002).
1http://www.dkma.dk
Statistical Analyses
Mean and standard deviation were used as descriptive statistics.
Crude and adjusted hazard ratios (HRs), and 95% confidence
intervals were calculated. Cox proportional hazard regression
models were used to analyze the time to fracture in exposed vs.
non-exposed subjects. The proportional hazard assumption was
checked through inspection of survival plots. In addition, in the
Cox regression models there was also tested for age and gender
interaction. In order to avoid immortal time bias, patients are
excluded from further risk analysis after subsequent stroke/TIA
events.
Analyses were performed using STATA 9.0 (STATA Corp.,
College Station, TX, United States) and IBM SPSS 19.0
(SPSS Inc.).
RESULTS
Baseline Characteristics of Users and
Non-users
Clopidogrel-treated and untreated controls were well matched
for both gender and age and the baseline variables in the two
groups are shown in Table 1. Not surprisingly, the fraction of
individuals with prior cerebral incidents such as ischaemic and
haemorrhagic stroke and TIA were significantly higher in the
clopidogrel group than in the control group. Also, the fraction
of individuals with other cardiovascular diseases (myocardial
infarction, heart failure, atherosclerosis and angina pectoris)
was significantly higher among clopidogrel-users than in non-
users. Moreover, the proportion of subjects on prior statin,
ACE inhibitors, beta blockers, diuretics and other anti-platelet
inhibitors was higher amongst users than in controls (Table 1).
Fracture Risk of Cerebral Ischemic
Events
The risk of fracture following TIA, ischaemic stroke and
haemorrhagic stroke was calculated. A clear association between
all three types of cerebral ischemic events and the risk of fracture
was detected (Table 2). Ischemic stroke increased the risk of
any fracture by approximately 50% while haemorrhagic stroke
increased the risk by approximately 30%. Surprisingly, TIA also
increased the risk of fracture to the same extent as haemorrhagic
stroke. Even after adjusting for multiple confounders, a 14%
increased risk of any fracture was seen in patients with ischaemic
stroke and 19% increased risk of hip fractures was seen in patients
with haemorrhagic stroke (Table 3).
As fracture risk is affected by gender, we stratified accordingly.
Interestingly, increased risk of fractures was only seen in men,
where it was significantly increased in men suffering ischaemic
stroke (any fracture) and in men suffering haemorrhagic stroke
(hip fracture) (Table 4).
Effect of Clopidogrel on Fracture Risk in
Stroke Patients
We have previously shown that clopidogrel treatment increased
fracture risk. Therefore, first we investigated whether clopidogrel
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TABLE 1 | Baseline characteristics of clopidogrel users and non-users.
Parameter Clopidogrel users (n = 77,503) Non-users (n = 232,510) P
Age (years, mean ± SD) 65.7 ± 12.7 65.7 ± 12.7 –
Men (number, %) 50,118 (64.7%) 150,354 (64.7%) –
Women (number, %) 27,385 (35.3%) 82,156 (35.3%)
Prior fracture 16,730 (21.6%) 47,795 (20.6%) <0.01
Prior diagnosis of alcoholism 2,469 (3.2%) 6,562 (2.8%) <0.01
Prior acute myocardial infarction 45,365 (58.5%) 10,709 (4.6%) <0.01
Prior angina pectoris 53,523 (69.1%) 21,428 (9.2%) <0.01
Prior heart failure 11,243 (14.5%) 8,129 (3.5%) <0.01
Prior peripheral atherosclerosis 7,356 (9.5%) 7,193 (3.1%) <0.01
Prior cerebral atherosclerosis 2,784 (3.6%) 2,900 (1.2%) <0.01
Prior diabetes 10,863 (14.0%) 11,894 (5.1%) <0.01
Prior atrial fibrillation 8,036 (10.4%) 12,080 (5.2%) <0.01
Prior systemic corticosteroids 20,050 (25.9%) 47,067 (20.2%) <0.01
Prior use of statins 30,345 (39.2%) 26,735 (11.5%) <0.01
Prior ACE/ARB use 38,658 (49.9%) 46,380 (19.9%) <0.01
Prior ACE/ARB plus diuretics use 6,529 (8.4%) 13,129 (5.6%) <0.01
Prior combined alpha/beta blocker 2,897 (3.7%) 3,187 (1.4%) <0.01
Prior use of other diuretics 8,737 (11.3%) 16,926 (7.3%) <0.01
Prior use of betablockers 36,288 (46.8%) 43,114 (18.5%) <0.01
Prior use of betablocker combinations 562 (0.7%) 1,249 (0.5%) <0.01
Prior use of calcium antagonists 27,953 (36.1%) 41,744 (18.0%) <0.01
Prior thiazide diuretic use 24,895 (32.1%) 53,675 (23.1%) <0.01
Prior loop diuretic use 18,105 (23.4%) 31,725 (13.6%) <0.01
Prior use of dipyridamole 8,123 (10.5%) 7,331 (3.2%) <0.01
Prior use of low dose ASA 44,015 (56.8%) 54,610 (23.5%) <0.01
Charlson index 2.1 ± 1.9 0.8 ± 1.5 <0.01
Income in index year (Danish crowns) 209,223 ± 315,460 224,149 ± 227,691 <0.01
Living with someone 29,030 (37.5%) 88,901 (38.2%) <0.01
Bronchodilator drugs 23,900 (30.8%) 54,703 (23.5%) <0.01
Drugs for smoking cessation 1,969 (2.5%) 2,240 (1.0%) <0.01
Spironolactone 11,292 (14.6%) 11,889 (5.1%) <0.01
Prior haemorrhagic stroke 924 (1.2%) 2,004 (0.9%) <0.01
Prior ischemic stroke 7,227 (9.3%) 6,077 (2.6%) <0.01
Prior TIA 5,573 (7.2%) 5,366 (2.3%) <0.01
Figures are numbers and % or mean and standard deviation (SD). ACE: Angiotensin-converting enzyme inhibitor, ARB, angiotensin receptor blocker; ASA, acetylsalicylic
acid.
TABLE 2 | The frequency and risk of any fracture are presented.
Crude relative risk Any fracture Hip fracture Forearm fracture Spine fracture
IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI)
Clopidogrel 1.05 (1.02–1.09)∗∗ 1.00 (0.94–1.07) 1.03 (0.97–1.10) 1.13 (0.99–1.28)
TIA 1.28 (1.20–1.36)∗∗∗ 1.50 (1.32–1.71)∗ 1.18 (1.00–1.38)∗ 1.34 (1.00–1.79)∗
Ischaemic stroke 1.54 (1.46–1.64)∗∗∗ 1.55 (1.24–1.92)∗ 1.15 (0.87–1.53) 1.80 (1.17–2.78)∗
Haemorrhagic stroke 1.34 (1.18–1.51)∗∗∗ 2.17 (1.96–2.40)∗ 1.18 (1.03–1.36)∗ 1.73 (1.37–2.17)∗
Previous fracture 2.41 (2.34–2.48)∗∗∗ 2.88 (2.72–3.04)∗ 2.33 (2.20–2.48)∗ 2.61 (2.33–2.93)∗
Risk of fracture is presented as crude relative risk and 95% confidence intervals in exposed individuals as compared to non-exposed (controls). Each individual row
represents the risk of fracture of one exposure variable (e.g., clopidogrel) when adjusted for the other exposures. CI, confidence interval; IRR, incidence rate ratio;
∗Two-tailed P < 0.05, ∗∗Two-tailed P < 0.01, ∗∗∗Two-tailed P < 0.001.
treatment affected the fracture risk in the different categories of
patients. In subjects with ischaemic stroke or TIA, no additional
increase in fracture risk could be detected (Figures 1A,B).
However, in subjects with haemorrhagic stroke, there was
a striking change in fracture risk 6 years after the event. In
clopidogrel-treated subjects, the risk leveled out and approached
the risk in patients without stroke, while the risk in subjects not
treated with clopidogrel increased dramatically (Figure 1C).
Frontiers in Pharmacology | www.frontiersin.org 4 November 2017 | Volume 8 | Article 821
fphar-08-00821 November 17, 2017 Time: 19:11 # 5
Jørgensen et al. Clopidogrel and Fractures in Stroke Patients
TABLE 3 | The risk of any fractures and of the three major groups of osteoporotic fractures (hip, forearm, and spine) is presented.
Crude relative risk Any fracture Hip fracture Forearm fracture Spine fracture
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Clopidogrel 0.85 (0.82–0.88)∗ 0.65 (0.61–0.69)∗ 0.90 (0.84–0.97)∗ 0.77 (0.67–0.88)∗
TIA 1.05 (0.98–1.13) 1.13 (0.99–1.30) 1.08 (0.91–1.28) 1.09 (0.81–1.48)
Ischaemic stroke 1.14 (1.07–1.21)∗ 1.02 (0.82–1.28) 0.98 (0.74–1.30) 1.12 (0.80–1.93)
Haemorrhagic stroke 1.04 (0.92–1.17) 1.19 (1.06–1.33)∗ 0.97 (0.84–1.13) 1.07 (0.84–1.38)
Risk of fracture is presented as crude relative risk, hazard ratio adjusted for multiple confounders. Each individual row represents the risk of fracture of one exposure
variable (e.g., clopidogrel) when adjusted for the other exposures. Multiple confounders: Prior alcoholism, prior fractures, Charlson index, income, living alone or not,
spironolactone use, use of bronchodilator drugs (proxy for smoking), use of drugs for smoking cessation (proxy for smoking), systemic corticosteroids, statin use, ACE
use, ACE + diuretics use, combined alpha plus betablocker use, other diuretics use, betablocker use, betablocker plus other drug combined, calcium channel blocker,
thiazide diuretics, loop diuretics, dipyridamole use, and acetylsalicylic use. HR, Hazard Ratio; CI, Confidence Interval; TIA, Transitory Ischemic Attack. ∗Two-tailed P < 0.05.
TABLE 4 | The risk of any fractures and of hip fractures stratified by gender is presented as crude relative risk, hazard ratio adjusted for multiple confounders.
Crude relative risk Any fracture HR (95% CI) Hip fracture HR (95% CI)
Men Women Men Women
Clopidogrel 0.82 (0.78–0.87)∗ 0.88 (0.84–0.93)∗ 0.56 (0.51–0.62)∗ 0.74 (0.68–0.81)∗
TIA 1.08 (0.98–1.20) 1.01 (0.92–1.10) 1.14 (0.92–1.40) 1.09 (0.91–1.30)
Ischaemic stroke 1.20 (1.09–1.31)∗ 1.08 (0.99–1.17) 1.11 (0.82–1.51) 0.94 (0.69–1.29)
Haemorrhagic stroke 1.04 (0.87–1.23) 1.06 (0.89–1.25) 1.35 (1.14–1.59)∗ 1.06 (0.91–1.23)
Each individual row represents the risk of fracture of one exposure variable (e.g., clopidogrel) when adjusted for the other exposures. Multiple confounders: Prior alcoholism,
prior fractures, Charlson index, income, living alone or not, spironolactone use, use of bronchodilator drugs (proxy for smoking), use of drugs for smoking cessation (proxy
for smoking), systemic corticosteroids, statin use, ACE use, ACE + diuretics use, combined alpha plus betablocker use, other diuretics use, betablocker use, betablocker
plus other drug combined, calcium channel blocker, thiazide diuretics, loop diuretics, dipyridamole use, and acetylsalicylic use. HR, Hazard Ratio; CI, Confidence Interval;
TIA, Transitory Ischemic Attack. ∗Two-tailed P < 0.05.
Interestingly, when adjusting for multiple confounders
clopidogrel treatment was associated with a reduced risk of
all fracture types evaluated with a reduction in fracture risk
between 10 and 35% (Table 3). Moreover, men had a more
pronounced reduction in fracture risk than women for both any
fracture (HR: 0.82 vs. 0.88, men and women, respectively) and
for hip fracture (HR: 0.56 vs. 0.74) (Table 4).
As previous studies have shown a dose-dependent biphasic
association between clopidogrel and fracture risk, we next
stratified according to dose expressed as DDD/day. For all
fracture types evaluated, the fracture risk was reduced by
10–46%, when DDD/day < 0.80. In contrast, for doses 0.8
DDD/day, fracture risk was either unaltered (any fracture and
spine fractures), marginally reduced (hip fractures) or marginally
increased (forearm fractures) when compared to individuals who
never used clopidogrel (Table 5). Again, when stratifying for
gender, the risk reducing effect was more pronounced in men
than in women and for hip fractures than for any fracture
(Table 6).
DISCUSSION
In the present study, we observed a clear association between
occurrence of stroke and risk of osteoporotic fractures. Moreover,
we found that patients treated with the P2Y12 inhibitor,
clopidogrel, overall had minimally affected fracture risk when
compared to non-users. However, when stratifying for dosage
and duration expressed as DDD/day, we found that the fracture
risk was reduced by as much as 50% for less adherent patients
while adherent patients treated with the recommended dose had
the same fracture risk as non-users.
It is well known that immobilization following a stroke leads
to increased bone resorption and decreased bone formation (Sato
et al., 2000) and bone loss (Ramnemark et al., 1999). Excessive
bone loss is a clear risk factor of osteoporosis and subsequently
fractures. Also, stroke patients have a significantly increased
incidence of falls, which aggravates the risk of osteoporotic
fractures in these patients. A recent meta-analysis included 13
cohorts of stroke survivors and found a 50% increased risk of hip
fracture in the stroke patients compared to men and women of
the same age (Yuan et al., 2016). This corresponds well with our
findings, where we see a 50% increase in risk in both any fracture
and hip fracture in patients with ischaemic stroke, while the risk
of spine fractures increase by as much as 80%. The increase in
fracture risk is even higher in patients with haemorrhagic stroke,
where risk of hip fractures is increased by as much as 120%.
Hip fractures are especially serious in stroke patients, as hip
fractures are associated with a high mortality, disability, loss of
independence, and high medical costs.
Interestingly TIA was also associated with an increase in
fracture risk of between 18 and 50%, but after adjusting
for multiple confounders no increased fracture risk could be
detected. In these patients, symptoms of the ischaemic attack
would disappear within 24 h. However, TIA patients may have
underlying common risk factors for fracture and stroke, or they
might have minor, undetected neurological deficits after the TIA
that affects balance and increases fall incidence as well as they
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FIGURE 1 | Cumulative hazard of any fracture as a function of time in years
since index event. Both transitory ischemic attack (TIA) (A) and ischaemic
stroke (IS) (B) increase the risk of any fracture and the risk continues to
increase during the years after the event. Clopidogrel treatment does not
seem to further increase the fracture. In patients with haemorrhagic stroke
(HS) there is also an increased risk of fractures (C). Again, clopidogrel does
not affect the fracture risk until 6 years after the event. After 6 years there is a
striking increase in risk in non-clopidogrel treated patients, while the risk in
clopidogrel-users levels out and equals the risk in non-stroke subjects. NS:
non-stroke/non-TIA.
have an increased risk of developing more severe stroke at a later
time point the clinician should still evaluate the fracture risk and
bone health of these patients.
To our knowledge, this is the first study to investigate
the association between fracture risk and clopidogrel use in
stroke and TIA patients. It is particularly important to elucidate
the effect of clopidogrel in stroke patients. First, they are
at increased risk of osteoporosis and subsequent fractures
due to immobilization and fall tendency and they are more
vulnerable than other patient. Next, we have previously shown
that clopidogrel treatment is associated with an increased risk
of fracture in a nationwide cohort study including all patients
prescribed clopidogrel Denmark (Jørgensen et al., 2012). Finally,
we found that the patients with the highest risk where those
receiving long-term treatment (more than 1 year) and as
clopidogrel treatment in stroke patients is life-long, it is highly
relevant to address the association of clopidogrel treatment on
fracture risk in this particular patient category. In contrast to
our previous study that included patients prescribed clopidogrel
for any indication, we only find a marginally increased risk
of osteoporotic fractures, and after adjusting for multiple
confounders known to predispose to osteoporosis and fractures,
we actually find a reduced risk of all fracture types. This is
even more pronounced when we stratify for dose, where less
adherent patients have even more reduced fracture risk as
compared to both non-users and adherent patients receiving
recommended doses. The obvious explanation for this would
be that clopidogrel, at least in lower doses or shorter duration,
affects bone metabolism and protects against fractures. This is
supported by an in vivo study in which P2Y12 null mice had
reduced osteoclastic activity and were partially protected against
pathological bone loss (Su et al., 2012). However, another in vivo
study from our own group found that clopidogrel treatment
of mice induced bone loss and reduced bone strength (Syberg
et al., 2012), so the effects of clopidogrel on bone cells and bone
metabolism are not fully elucidated yet. Another explanation for
the reduced fracture risk in less adherent patients could be that
these patients stop the treatment due to side effects or they could
be more severely affected by the stroke and are thus completely
immobilized and thus in bed for prolonged periods of time, thus
reducing the risk of falls and subsequent fractures.
As fracture risk differs between men and women we stratified
the analyses according to gender. Interestingly, we found that
clopidogrel treatment in men is associated with a lower fracture
risk than in women. It has previously been shown that the effects
of clopidogrel on platelet function are gender dependent (Hobson
et al., 2009; Patti et al., 2014), and our data suggests that this might
be a more universal gender-specific effect of clopidogrel in all
target organs. However, differences in underlying comorbidities
could also lead to over- or underadjustment for confounders in
the analyses, falsely demonstrating an effect of gender on the
response to clopidogrel.
Due to the centrally organized healthcare system in Denmark,
a broad range of healthcare information is collected and can
be collated based on the unique identification number for each
citizen in Denmark. This enabled us to perform a large-scale
population-based designed study. This also made it possible to
collect data on confounders and exposure before the occurrence
of fracture, thereby eliminating the risk of recall bias. Moreover,
as all collected prescriptions are registered with the Danish
Medicines Agency, it has been possible to include all patients
prescribed clopidogrel in the study, thereby reducing the risk of
selection bias. Finally, as almost all fractures are treated in public
emergency departments and hospitals covered by the databases,
collection of fracture data is considered almost complete, though
there can be a minor risk of coding errors by the discharging
physicians.
Though the strength of the study is the large-scale design,
the optimal design would have been a prospective, randomized
trial as optimal confounder-control could have been obtained.
Such study should have included the determination of circulating
markers of bone turnover to determine the effects of clopidogrel
on bone formation and bone resorption in the patients. However,
it would not have been feasible to conduct such a trial, as the cost
of a sufficiently powered study with fracture as endpoint would
have been immense. Moreover, it is not ethically justifiable to
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TABLE 5 | The risk of any fractures and of the three major groups of osteoporotic fractures (hip, forearm, and spine) by dose of clopidogrel in all users.
Crude relative risk Any fracture HR (95% CI) Hip fracture HR (95% CI) Forearm fracture HR (95% CI) Spine fracture HR (95% CI)
Clopidogrel (never use as reference)
<0.1 DDD/day 0.77 (0.74–0.81)∗ 0.54 (0.48–0.60)∗ 0.83 (0.74–0.92)∗ 0.77 (0.63–0.94)∗
0.1–0.39 DDD/day 0.81 (0.760.85)∗ 0.62 (0.55–0.69)∗ 0.81 (0.72–0.91)∗ 0.64 (0.50–0.80)∗
0.40–0.79 DDD/day 0.86 (0.80–0.92)∗ 0.60 (0.52–0.70)∗ 0.96 (0.83–1.12) 0.69 (0.51–0.94)∗
≥0.8 DDD/day 1.04 (0.99–1.11) 0.90 (0.81–1.00)∗ 1.14 (1.00–1.29)∗ 1.00 (0.79–1.25)
TIA 1.04 (0.97–1.11) 1.10 (0.96–1.26) 1.05 (0.89–1.25) 1.07 (0.79–1.44)
Ischaemic stroke 1.11 (1.04–1.18)∗ 1.02 (0.82–1.27) 0.98 (0.74–1.30) 1.24 (0.80–1.92)
Haemorrhagic stroke 1.04 (0.92–1.17) 1.14 (1.02–1.28)∗ 0.94 (0.81–1.10) 1.04 (0.81–1.34)
Risk of fracture is presented as crude relative risk, hazard ratio adjusted for multiple confounders. Each individual row represents the risk of fracture of one exposure
variable (e.g., clopidogrel) when adjusted for the other exposures. Multiple confounders: Prior alcoholism, prior fractures, Charlson index, income, living alone or not,
spironolactone use, use of bronchodilator drugs (proxy for smoking), use of drugs for smoking cessation (proxy for smoking), systemic corticosteroids, statin use, ACE
use, ACE + diuretics use, combined alpha plus betablocker use, other diuretics use, betablocker use, betablocker plus other drug combined, calcium channel blocker,
thiazide diuretics, loop diuretics, dipyridamole use, and acetylsalicylic use. HR, Hazard Ratio; CI, Confidence Interval; TIA, Transitory Ischemic Attack. ∗Two-tailed P < 0.05.
TABLE 6 | The risk of any fractures and of the three major groups of osteoporotic fractures (hip, forearm, and spine) by dose of clopidogrel stratified by gender.
Crude relative risk Any fracture HR (95% CI) Hip fracture HR (95% CI)
Men Women Men Women
Clopidogrel (never use as reference)
<0.1 DDD/day 0.78 (0.72–0.83)∗ 0.80 (0.75–0.86)∗ 0.49 (0.42–0.58)∗ 0.61 (0.53–0.70)∗
0.1–0.39 DDD/day 0.81 (0.75–0.87)∗ 0.86 (0.79–0.92)∗ 0.52 (0.44–0.62)∗ 0.76 (0.66–0.87)∗
0.40–0.79 DDD/day 0.81 (0.73–0.90)∗ 0.93 (0.84–1.03) 0.52 (0.41–0.66)∗ 0.70 (0.58–0.85)∗
≥0.8 DDD/day 0.97 (0.89–1.07) 1.01 (0.93–1.08) 0.79 (0.66–0.94)∗ 0.91 (0.80–1.04)
TIA 1.07 (0.97–1.19) 0.99 (0.91–1.09) 1.11 (0.90–1.36) 1.06 (0.89–1.27)
Ischaemic stroke 1.17 (1.07–1.29)∗ 1.05 (0.96–1.15) 1.11 (0.82–1.51) 0.94 (0.69–1.29)
Haemorrhagic stroke 1.03 (0.87–1.23) 1.06 (0.89–1.25) 1.31 (1.11–1.54)∗ 1.02 (0.88–1.19)
Risk of fracture is presented as crude relative risk, hazard ratio adjusted for multiple confounders. Each individual row represents the risk of fracture of one exposure
variable (e.g., clopidogrel) when adjusted for the other exposures. Multiple confounders: Prior alcoholism, prior fractures, Charlson index, income, living alone or not,
spironolactone use, use of bronchodilator drugs (proxy for smoking), use of drugs for smoking cessation (proxy for smoking), systemic corticosteroids, statin use, ACE
use, ACE + diuretics use, combined alpha plus betablocker use, other diuretics use, betablocker use, betablocker plus other drug combined, calcium channel blocker,
thiazide diuretics, loop diuretics, dipyridamole use, and acetylsalicylic use. HR, Hazard Ratio; CI, Confidence Interval; TIA, Transitory Ischemic Attack. ∗Two-tailed P < 0.05.
conduct a placebo-controlled trial, as clopidogrel is part of the
standard, recommended treatment after an ischaemic stroke as
well as after other cardiovascular diseases.
In our study, we have extensively controlled for multiple
confounders in relation to fractures, but as in all observational
studies there might still be residual confounding because of
possible differences in comorbidities. Especially, the choice of
prescribing clopidogrel to the stroke patient is dependent on the
type of stroke (haemorrhagic, ischaemic) and possibly also the
general condition of the patient. Thus, the severity of neurological
deficit after the cerebrovascular event might be different between
the treatment groups, which we are not able to control for with
the current design. Also, differences in extent of exercise and
mobilization and thus the risk of falls has not been possible
to adjust for, as this information is not contained in any
registers.
Future studies should address the effects of the newer P2Y12
receptor antagonists, prasugrel and ticagrelor, as they have other
modes of function on the receptor. However, as they were
marketed later than clopidogrel and have not been implemented
as part of the standard of care in the treatment of stroke in
Denmark, the number of patients treated would not be sufficient
and the study therefore not sufficiently powered to determine the
effects on osteoporotic fractures.
CONCLUSION
Patients with stroke have increased risk of osteoporotic fractures,
but treatment with the widely used platelet inhibitor, clopidogrel,
does not seem to increase the risk of fractures. In contrast, less
adherent patients have lower risk of fractures than non-users.
This might be due to a bone-protective effect of clopidogrel at
lower doses or it might be due to differences in comorbidities
between patients exposed to suboptimal doses of clopidogrel and
patients treated with recommended doses. Thus, clopidogrel is
not associated with deleterious effects on bone in stroke patients,
but might even reduce the risk of fracture in these patients.
However, further studies should investigate the exact effects of
clopidogrel on bone metabolism.
Finally, in light of the high risk of fractures in stroke patient
per se and the large number of underlying risk factors, careful
attention should be given to the bone status of these patients.
Clinicians should carefully consider additional evaluation
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of the bone status of stroke survivors and treatment should be
given to prevent development or progression of osteoporosis.
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